Gene Therapy for HER-Positive Cancer (SENTRY-HER2)

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

HER2 Expressing Solid Tumors

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Valkyrie Clinical Trials, Los Angeles, California, United States
Contact: Study coordinator (Myo Zaw) · clinicaltrials@vctcare.com · 424-535-1874
SCRI Denver DDU at HealthOne, Denver, Colorado, United States
Contact: Study coordinator (Julia Etchart) · julia.etchart@sarahcannon.com · 805-701-0185
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Contact: Study coordinator (Jamie Walters) · waltersj@mskcc.org · 917-843-7966
Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia, Pennsylvania, United States
Contact: Study coordinator (Steven Manobianco, MD) · steven.manobianco@jefferson.edu · 215-955-8874
SCRI Oncology Partners, Nashville, Tennessee, United States
Contact: Study coordinator (SCRI Referrals) · SCRI.DDUreferrals@scri.com · 615-329-7274
UT MD Anderson Cancer Center, Houston, Texas, United States
Contact: Study coordinator (Christine Tran) · cmtran@mdanderson.org · 832-803-8328

View source on ClinicalTrials.gov Contact study team (email)